Sputnik’s ‘efficacy at 95%’, to be cheaper than US vaccines

Russia’s Sputnik V Covid-19 vaccine, that reported an efficacy of over 95%, will be twice as cheap as those by Pfizer and Moderna with similar positive results. Sputnik V, developed by Gamaleya Institute and RDIF (Russian Direct Investment Fund), will be priced under $20 per person for the two doses in global markets, including India, and may be available here by February.